文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

阿片类药物减量与大剂量长期阿片治疗患者阿片过量及阿片使用障碍的关联

Association of Opioid Dose Reduction With Opioid Overdose and Opioid Use Disorder Among Patients Receiving High-Dose, Long-term Opioid Therapy in North Carolina.
PubMed 文献 · JAMA Netw Open · 2022-04-01
一句话结论对接受大剂量长期阿片治疗的患者,快速减量或突然停药与阿片过量和阿片使用障碍风险升高相关。

该回顾性队列研究纳入2006年1月至2018年9月期间接受大剂量长期阿片治疗(≥90每日吗啡毫克当量,且覆盖90天中≥90%时间)的18至64岁患者19 443例,随访至入组后4年。与逐渐减量相比,快速减量或停药与第一年后致命及非致命过量风险升高相关(第1年HR 1.43,95%CI 0.94-2.18;第2-4年HR 1.95,95%CI 1.31-2.90)。快速减量或停药与诊断阿片使用障碍在随访2年内无关联,但随访25至48个月时风险升高(HR 1.28,95%CI 1.01-1.63)。作者认为,这些发现强化了既往对大剂量长期阿片治疗患者快速减量安全性的担忧,并强调减量时需谨慎。

要点

  • 快速减量或停药(>10%剂量/周)与大剂量长期阿片治疗患者第2-4年致命及非致命过量风险升高相关(HR 1.95,95%CI 1.31-2.90)。
  • 第1年快速减量或停药与过量风险关联未达统计学显著(HR 1.43,95%CI 0.94-2.18)。
  • 随访25至48个月时,快速减量或停药者新发阿片使用障碍风险升高(HR 1.28,95%CI 1.01-1.63);2年内无关联。
  • 作者认为,这些发现强化了既往对大剂量长期阿片治疗患者快速减量安全性的担忧,并强调减量时需谨慎。

适用人群与场景

  • 18至64岁、接受大剂量长期阿片治疗(≥90每日吗啡毫克当量,且覆盖90天中≥90%时间)的患者,数据来自北卡罗来纳州一家大型私人医疗保险公司2006年1月至2018年9月的理赔数据。

诊断标准与关键阈值

  • 大剂量长期阿片治疗定义为≥90每日吗啡毫克当量,且该剂量覆盖90天中≥90%的时间。
  • 快速减量或停药定义为剂量减少>10%/周,与维持、增加或逐渐减量或停药相对比。

研究设计与关键结果

  • 研究类型为回顾性队列研究,共纳入19 443例接受大剂量长期阿片治疗的患者,中位年龄49岁(IQR 41-55),男性10 073例(51.8%),随访至入组后4年。
  • 与逐渐减量相比,快速减量或停药与第一年后致命及非致命过量风险升高相关(第1年:HR 1.43,95%CI 0.94-2.18;第2-4年:HR 1.95,95%CI 1.31-2.90)。
  • 快速减量或停药与诊断阿片使用障碍在随访2年内无关联;但随访25至48个月时,快速减量或停药者新发阿片使用障碍风险升高(HR 1.28,95%CI 1.01-1.63)。
  • 采用逆概率加权累积发生率及边际结构Fine-Gray模型估计风险比,并考虑竞争风险。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这些发现强化了既往对大剂量长期阿片治疗患者快速减量安全性的担忧,并强调减量时需谨慎。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Rapid reduction or discontinuation of long-term opioid therapy may increase risk of opioid overdose or opioid use disorder (OUD). Current guidelines for chronic pain management caution against rapid dose reduction but are based on limited evidence.

OBJECTIVE: To characterize the association between rapid reduction or abrupt discontinuation of opioid therapy (vs maintained or gradual reduction) and incidence of opioid overdose and OUD among patients prescribed high-dose, long-term opioid therapy (HDLTOT).

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was conducted among patients aged 18 to 64 years who were prescribed HDLTOT (≥90 daily morphine milligram equivalents for ≥90% of 90 days) from January 2006 to September 2018, with follow-up up to 4 years after cohort entry. Claims data were drawn from a large private health insurer in North Carolina and analyzed from March 1, 2006, to September 30, 2018.

EXPOSURES: Time-varying exposure of rapid dose reduction or discontinuation (>10% dose reduction/week) vs maintenance, increase, or gradual reduction or discontinuation.

MAIN OUTCOMES AND MEASURES: The main outcome was incident opioid overdose (fatal or nonfatal) or diagnosed OUD. Inverse probability-weighted cumulative incidence of outcomes were estimated using the cumulative incidence function and hazard ratios (HRs) using marginal structural Fine-Gray models as a function of rapid dose tapering or discontinuation (vs gradual reduction or discontinuation or maintained or increased), accounting for competing risks.

RESULTS: A total of 19 443 patients (median [IQR] age, 49 [41-55] years; 10 073 [51.8%] men) who received HDLTOT were identified. Rapid reduction or discontinuation was associated with higher risk of fatal and nonfatal overdoses compared with gradual reduction after the first year (year 1: HR, 1.43; 95% CI, 0.94-2.18; years 2-4: HR, 1.95; 95% CI, 1.31-2.90). There was no association between rapid reduction or discontinuation and diagnosed OUD through 2 years of follow-up; however, the hazard of incident OUD among patients exposed to rapid tapering or discontinuation was greater 25 to 48 months after the start of follow-up (HR, 1.28; 95% CI, 1.01-1.63).

CONCLUSIONS AND RELEVANCE: In this cohort study, rapid dose reduction or discontinuation was associated with increased risk of opioid overdose and OUD during long-term follow-up. These findings reinforce prior concerns about safety of rapid dose reductions for patients receiving HDLTOT and highlight the need for caution when reducing opioid doses.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. DiPrete BL, Ranapurwala SI, Maierhofer CN, et al. Association of Opioid Dose Reduction With Opioid Overdose and Opioid Use Disorder Among Patients Receiving High-Dose, Long-term Opioid Therapy in North Carolina. JAMA Netw Open. 2022. PMID: 35476064. doi:10.1001/jamanetworkopen.2022.9191

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。